Sino-Swed Tongkang Bio-Tech (Shenzhen) Co. Ltd. of Shenzhen at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Sino-Swed Tongkang Bio-Tech (Shenzhen) Co. Ltd.

19F, A2 Bldg, Kexing Science Park, 15 Keyuan Rd., Nanshan, 518057 Shenzhen
Telephone +86 755 33640226
Fax +86 755 33640226

This company is co-exhibitor of
Shenzhen Association of Medical Devices

Hall map

MEDICA 2019 hall map (Hall 17): stand C01

Fairground map

MEDICA 2019 fairground map: Hall 17

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.02  Molecular biomarkers

Our products

Product category: Molecular biomarkers

Protein Blocking Reagent.


1.For block purposes in the Dot blot Assay.
2.Reduce Biovin,reduce the cross-reaction.
3. 10g/bag

More Less

Product category: Molecular biomarkers

Thymidine Kinase 1 Cell Cycle Assay Kit

Product Features:

1. Use high sensitive enhanced chemiluminescent (ECL) dot blot assay; Low detection limit; High specificity.
2. Can be applied to health screening, cell proliferation evaluation before cancer formed and tumor risk prevention.
3. Can be applied to malignancy evaluation, treatment monitoring and prognosis evaluation for various of solid tumors, ? ?lymphoma and leukaemia, etc.
4. Can be applied to evaluation for recurrence risk detection.

More Less

Product category: Molecular biomarkers

Incubator Cabinet


Keep stable temperature for incubation purposes.

More Less

About us

Company details

Sino-Swed Tongkang Biotech Limited (Shenzhen) is founded since 2002, which is an innovative bio-technology company which inherits the most advanced medical value and concepts from Sweden.

SSTK devotes itself to the research and development of assessment techniques and evaluation solution for critical illness. It works closely with global leading research institutions to transform the highly scientific achievements into practical industrial operation.

World’s first cell cycle theory was established by SSTK, with quantitative assessment of thymidine kinase 1 (TK1) as a core marker for proliferation rate, provide solutions from tumor early risk prediction, tumor prognosis assessment, precise treatment of dynamic tracking to recurrence / metastasis risk assessment.

After decade research and development in SSTK, we got patents and developed application standards in the area of cell proliferation with the invention of multiple detection methods for TK1, and we became the first approved clinical application of detection reagents and methods for TK1 worldwide. Application methods are incorporated into a number of expert consensus, application path and clinical guidelines. Our products had covered 90% of China's provinces and cities of high-end medical and health management agencies, and has entered the overseas market.

SSTK continues the partnership with the internationally renowned biomedical and tumor biology research team, e.g. with the Nobel Review Agency - Karolinska Institute (, Sweden, established Sino-Swed Molecular Biomedical Research Institute together with Swedish experts and Chinese physicians. SSTK lead a number of major technology of medical transformation, to the realization of technological innovation and continuous iterative update based on the previous results from our global research team.

SSTK has advanced manufacturing system for immuno-diagnostic reagents and medical equipment, and passed the ISO13485 international quality certification and the Chinese medical equipment quality management certification.

Management layer of SSTK have wealthy experience in IVD area, led the group to the professional, standardized direction.

More Less